GlassScriptPhysician profile
Joseph E Pinciotti
NPI 1265460539
$5,816.63
in general payments reported to CMS, 2019-2025
35 companies · $3,074 in 2025
The $3,074 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.05 · 2020: $35.03 · 2021: $26.67 · 2022: $15.98 · 2023: $120 · 2024: $2,504 · 2025: $3,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,686 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,686.34 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,033.90 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $600.48 | 2023-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $459.68 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $395.08 | 2024-2025 | Veozah |
| Abbvie INC. | $390.37 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $340.56 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $305.68 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $289.04 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.34 | 2024-2025 | Xifaxan |
| Pfizer INC. | $226.42 | 2023-2025 | |
| Lundbeck LLC | $165.67 | 2024-2025 | Rexulti |
| Dexcom, INC. | $150.90 | 2024-2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $130.92 | 2024-2025 | Jatenzo |
| Esperion Therapeutics, INC. | $120.48 | 2024-2025 | Nexletol |
| Gilead Sciences, INC. | $119.01 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $86.27 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.79 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $80.50 | 2024-2025 | Spravato |
| Glaxosmithkline, LLC. | $72.13 | 2024-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $71.88 | 2024-2025 | Korlym |
| Orexo US, INC. | $71.76 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.50 | 2025 | Caplyta |
| Shield Therapeutics INC | $53.97 | 2025 | |
| Axsome Therapeutics, INC. | $37.49 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $34.56 | 2024 | |
| Tris Pharma INC | $34.35 | 2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $32.29 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $27.44 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ironshore Pharmaceuticals INC. | $20.98 | 2024 | |
| Alkermes, INC. | $20.37 | 2020 | |
| Seqirus USA INC | $15.84 | 2025 | Fluad, Flucelvax |
| Corium, LLC | $15.60 | 2024 | Azstarys |
| Redhill Biopharma INC. | $14.66 | 2020 | |
| Genentech USA, INC. | $11.94 | 2019 | |
| Theracosbio, LLC | $9.78 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pinciotti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.